» Articles » PMID: 29339504

Complement Pathway Gene Activation and Rising Circulating Immune Complexes Characterize Early Disease in HIV-associated Tuberculosis

Overview
Specialty Science
Date 2018 Jan 18
PMID 29339504
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

The transition between latent and active tuberculosis (TB) occurs before symptom onset. Better understanding of the early events in subclinical disease will facilitate the development of diagnostics and interventions that improve TB control. This is particularly relevant in the context of HIV-1 coinfection where progression of TB is more likely. In a recent study using [F]-fluoro-2-deoxy-d-glucose positron emission/computed tomography (FDG-PET/CT) on 35 asymptomatic, HIV-1-infected adults, we identified 10 participants with radiographic evidence of subclinical disease, significantly more likely to progress than the 25 participants without. To gain insight into the biological events in early disease, we performed blood-based whole genome transcriptomic analysis on these participants and 15 active patients with TB. We found transcripts representing the classical complement pathway and Fcγ receptor 1 overabundant from subclinical stages of disease. Levels of circulating immune (antibody/antigen) complexes also increased in subclinical disease and were highly correlated with C1q transcript abundance. To validate our findings, we analyzed transcriptomic data from a publicly available dataset where samples were available in the 2 y before TB disease presentation. Transcripts representing the classical complement pathway and Fcγ receptor 1 were also differentially expressed in the 12 mo before disease presentation. Our results indicate that levels of antibody/antigen complexes increase early in disease, associated with increased gene expression of C1q and Fcγ receptors that bind them. Understanding the role this plays in disease progression may facilitate development of interventions that prevent this, leading to a more favorable outcome and may also be important to diagnostic development.

Citing Articles

Impact of Severity of COVID-19 in TB Disease Patients: Experience from an Italian Infectious Disease Referral Hospital.

Di Bari V, Cerva C, Libertone R, Carli S, Musso M, Goletti D Infect Dis Rep. 2025; 17(1).

PMID: 39997463 PMC: 11855733. DOI: 10.3390/idr17010011.


Plasma proteomics for novel biomarker discovery in childhood tuberculosis.

Fossati A, Wambi P, Jaganath D, Calderon R, Castro R, Mohapatra A medRxiv. 2024; .

PMID: 39677468 PMC: 11643232. DOI: 10.1101/2024.12.05.24318340.


Unmasking the hidden impact of viruses on tuberculosis risk.

Darboe F, Reijneveld J, Maison D, Martinez L, Suliman S Trends Immunol. 2024; 45(9):649-661.

PMID: 39181733 PMC: 11769684. DOI: 10.1016/j.it.2024.07.008.


Blood transcriptomic signatures for symptomatic tuberculosis in an African multicohort study.

Muwanga V, Mendelsohn S, Leukes V, Stanley K, Mbandi S, Erasmus M Eur Respir J. 2024; 64(2).

PMID: 38964778 PMC: 11325265. DOI: 10.1183/13993003.00153-2024.


Successful treatment of life-threatening mycobacteriosis using adjunctive gamma-interferon therapy with genetic analysis.

Confalonieri P, Maiocchi S, Salton F, Ruaro B, Rizzardi C, Volpe M IJTLD Open. 2024; 1(1):56-58.

PMID: 38919412 PMC: 11189599. DOI: 10.5588/ijtldopen.23.0406.


References
1.
Berry M, Graham C, McNab F, Xu Z, Bloch S, Oni T . An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature. 2010; 466(7309):973-7. PMC: 3492754. DOI: 10.1038/nature09247. View

2.
Bloom C, Graham C, Berry M, Rozakeas F, Redford P, Wang Y . Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One. 2013; 8(8):e70630. PMC: 3734176. DOI: 10.1371/journal.pone.0070630. View

3.
Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N . A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity. 2008; 29(1):150-64. PMC: 2727981. DOI: 10.1016/j.immuni.2008.05.012. View

4.
Schifferli J, Ng Y, PETERS D . The role of complement and its receptor in the elimination of immune complexes. N Engl J Med. 1986; 315(8):488-95. DOI: 10.1056/NEJM198608213150805. View

5.
Maertzdorf J, Weiner 3rd J, Mollenkopf H, Bauer T, Prasse A, Muller-Quernheim J . Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A. 2012; 109(20):7853-8. PMC: 3356621. DOI: 10.1073/pnas.1121072109. View